GlassScriptPhysician profile
Christopher J Pole
NPI 1285883231
$128,529.97
in general payments reported to CMS, 2019-2025
23 companies · $9,651 in 2025
The $9,651 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $209 · 2021: $358 · 2022: $74K · 2023: $33K · 2024: $11K · 2025: $9,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $49K · Food and Beverage: $3,769 · Travel and Lodging: $744 · Honoraria: $25.59 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $49,064.96 |
| Food and Beverage | $3,768.87 |
| Travel and Lodging | $744.01 |
| Honoraria | $25.59 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microsurgical Technology, INC. | $96,405.86 | 2022-2024 | |
| Rxsight INC | $27,890.90 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Glaukos Corporation | $1,271.35 | 2019-2025 | Idosetr, Istent Infinite, Idose |
| Alcon Vision LLC | $1,133.15 | 2019-2025 | Clareon, Rocklatan, Unity |
| The Cameron-Ehlen Group, INC. | $495.37 | 2021-2022 | |
| Allergan, INC. | $202.70 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $146.67 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $132.68 | 2019-2024 | Tecnis Iol |
| Ocular Therapeutix, INC. | $124.71 | 2022 | |
| Horizon Therapeutics Plc | $115.80 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $103.07 | 2025 | |
| Sun Pharmaceutical Industries INC. | $97.54 | 2019-2024 | |
| Harrow Eye, LLC | $91.94 | 2024-2025 | Iheezo |
| Beaver-Visitec International, INC. | $70.95 | 2025 | |
| Bausch & Lomb Americas INC. | $66.57 | 2024-2025 | Envista Envy Iol, Miebo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $54.08 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $48.14 | 2019 | |
| Eyevance Pharmaceuticals LLC | $19.44 | 2023 | Flarex |
| Mallinckrodt Enterprises LLC | $17.01 | 2019 | |
| Amgen INC. | $16.74 | 2025 | Tepezza |
| Abbvie INC. | $13.20 | 2023 | |
| Novartis Pharmaceuticals Corporation | $12.10 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Pole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.